Evaluating the potential of sNfL as biomarker for MS in UK: insights from SUNLIT survey

<h3></h3> The ongoing SUNLIT survey, led by the Novartis medical science liaisons in collaboration with the leading experts in MS, aimed to assess the utility of sNfL as a biomarker in MS for routine clinical practice in the UK. We surveyed a minimum of 60 MS specialists and 30 MS nurses who completed a 1-time questionnaire either face-to-face or virtually. The interim findings from 27 clinician interviews were positive supporting the use of sNfL if available (27/27; 100%), aiding treatment decisions (average score, 7 out of 10) and reducing frequency of MRI scans (16/27; 59%). Survey respondents preferred use of sNfL testing at treatment initiation (20/27, 74%) and in treatment-naïve patients (23/27; 85%). Neutral response was observed regarding understanding sNfL data in MS (mean score, 6 out of 10) and adoption in clinical practice (mean score, 5 out of 10), highlighting the need for additional education. Access to sNfL testing and potential confounders like age and BMI were identified as potential barriers to its implementation (≥67%). The findings from this survey will provide insights into the current perceptions and understanding of sNfL testing among MS specialists in the UK and guide the integration of sNfL as a speedy, cost-effective biomarker into routine clinical practice, ultimately improving patient outcomes.